

# Q3 2020 RESULTS

SANOFI  Empowering Life



“ We achieved strong growth in our treatment for type 2 inflammation disorders and vaccines during Q3. We helped transform the lives of thousands of patients and reduced the spread of vaccine-preventable diseases, even as we continue to fight COVID-19. ”

**PAUL HUDSON**

CHIEF EXECUTIVE OFFICER, SANOFI

## COMPANY SALES & BUSINESS EPS\*

Q3 2020 SALES\*

**€9,479M**  
+5.7% (-0.2%)

Q3 2020 BUSINESS EPS\*

**€1.83**  
+8.8% (+0.5%)

\*Growth rates are expressed at constant exchange rates (CER)  
Growth rates in parentheses are expressed on a reported basis.

**€2,753M**

Specialty Care

**€2,077M**

Vaccines

## SALES BY GLOBAL BUSINESS UNIT

**€3,608M**

General Medicines

**€1,041M**

Consumer Healthcare

## SALES BY GEOGRAPHY

U.S.

**€3,974M**

EUROPE

**€2,272M**



REST OF THE WORLD

**€3,233M**

of which:

China **€655M**

Japan **€390M**

Brazil **€169M**

Russia **€140M**

## SANOFI'S ONGOING COMMITMENT AGAINST COVID-19

### Developing COVID-19 vaccines

#### Recombinant vaccine<sup>1</sup> candidate:

Phase 1 / 2 study initiated, results expected in December

#### mRNA vaccine<sup>2</sup> candidate:

Phase 1 / 2 study expected to start in December

### Ensuring global access

Sanofi and GSK to support COVAX with **200 million doses** of the recombinant vaccine candidate: COVAX Facility aims to secure successful and equitable access to COVID-19 vaccines worldwide

1 - In collaboration with GSK

2 - In collaboration with Translate Bio

For further information on Q3 results and definitions of financial indicators, please refer on the press release issued on October 29, 2020 at:

<https://www.sanofi.com/en/investors>



Sanofi.com



@Sanofi



Sanofi



@Sanofi

Sanofi.us



@SanofiUS



SanofiUS